Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00686317PMID 1628371
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose cisplatin in advanced head and neck cancer

  2004cited by this paper
• Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer

  2004cited by this paper
• Increased cisplatin tissue levels with prolonged arterial infusion in the rat

  1991cited by this paper
• Has chemotherapy proved itself in head and neck cancer?

  1990cited by this paper
• High‐dose cisplatin for locally advanced or metastatic head and neck cancer. A phase ii pilot study

  1989cited by this paper
• Head and neck cancer: chemotherapy concepts.

  1988cited by this paper
• Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study.

  1987cited by this paper
• Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer.

  1987cited by this paper
• Induction chemotherapy as initial treatment for advanced head and neck cancer: a model for the multidisciplinary treatment of solid tumors.

  1987cited by this paper
• The Pharmacokinetics of Cisplatin in Experimental Regional Chemotherapy

  1987cited by this paper
• Phase I study of continuous-infusion cisplatin.

  1986cited by this paper
• Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients.

  1986cited by this paper
• Single‐agent and combination‐drug regional chemotherapy for head and neck cancer using an implantable infusion pump

  1984cited by this paper
• Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).

  1983cited by this paper
• Clinical pharmacokinetics of intraarterial cisplatin in humans.

  1983cited by this paper
• Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

  1977cited by this paper
• Patterns of spread of distant metastases in head and neck cancer

  1972cited by this paper

• Interventional Oncology

  2022cites this paper
• miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.

  2018cites this paper
• Dysregulation of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901

  2017cites this paper
• Superselective Intra-arterial Infusion Chemotherapy with Nedaplatin for Oral Cancer: A Pharmacological Study of the Dose Clearance

  2015cites this paper
• Regionale Chemotherapie bei Kopf-Hals-Tumoren

  2013cites this paper
• Tannic acid, an inhibitor of poly(ADP-ribose) glycohydrolase, sensitizes ovarian carcinoma cells to cisplatin

  2012cites this paper
• Hydrogel containing L-valine residues as a platform for cisplatin chemotherapy.

  2011cites this paper
• Induction Chemotherapy in Head and Neck Cancers

  2011cites this paper
• The Interaction between a Drug and Ultrasound in Sonochemotherapy against Ovarian Cancers

  2010cites this paper
• The interaction between a drug and ultrasound in sonochemotherapy against ovarian cancers.

  2010cites this paper
• Treatment outcome of maxillary sinus cancer

  2009cites this paper
• Cisplatin/hydrogel complex in cancer therapy.

  2009cites this paper
• Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma

  2009cites this paper
• System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.

  2009cites this paper
• Long-term platinum retention after treatment with cisplatin and oxaliplatin

  2008cites this paper
• Prognostic factors and predictive tests in the treatment of head and neck squamous cell carcinoma

  2007cites this paper
• Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.

  2007cites this paper
• Inductively coupled plasma mass spectrometry: a unique, ultrasensitive tool for exploring the pharmacology of metal-based anticancer agents

  2007cites this paper
• The chemistry of dinuclear analogues of the anticancer drug cisplatin. A DFT/CDM study.

  2006cites this paper
• Potential advantages of loco-regional intra-arterial chemotherapy.

  2006cites this paper
• REDUCTION OF THE SYSTEMIC TOXICITY OF CISPLATIN FOR L,IVE:R MALIGNANCIES BY IN'TRA-ARTERIAL HEPATIC ROUTE ADMINISTRATION

  2006cites this paper
• Prediction of treatment outcome by cisplatin‐DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin‐radiation (RADPLAT)

  2006influential citation
• Targeting the beta‐catenin/APC pathway: a novel mechanism to explain the cyclooxygenase‐2‐independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

  2005cites this paper
• Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli

  2005cites this paper
• Cisplatin and radiation induced hearing loss in head and neck cancer patients

  2005cites this paper
• Interventionelle Therapie von Lebermetastasen

  2004cites this paper
• Intralesional chemotherapy for head and neck carcinoma: a review of the literature.

  2004cites this paper
• [Interventional therapy for liver metastases].

  2004cites this paper
• In vitro cytotoxic dose-relation of cisplatin and sodium thiosulphate in human tongue and oesophageal squamous carcinoma cell lines.

  2002cites this paper
• Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.

  2000cites this paper
• Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.

  2000cites this paper
• Intraarterial chemotherapy as neoadjuvant treatment of oral cancer.

  1999cites this paper
• Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation

  1997cites this paper
• Absence of whole body hyperthermia effect on cisplatin distribution in spontaneous canine tumors.

  1995cites this paper
• Reduction of the systemic toxicity of cisplatin by intra‐arterial hepatic route administration for liver malignancies

  1995cites this paper